Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, Długa 1/2, 61-848 Poznań, Poland.
Int J Environ Res Public Health. 2022 Mar 31;19(7):4156. doi: 10.3390/ijerph19074156.
Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to the treatment of hypertension is a response to increased compliance, especially in elderly patients. In our work, we describe in particular the possibilities of using β-adrenergic receptors blockers and angiotensin-converting enzyme inhibitors in combinations. The combinations of APIs are used as single pills in patients with arterial hypertension with concomitant diseases such as hyperlipidemia; blood coagulation problems and diabetes mellitus were also discussed successively. Pharmacoeconomic analysis for the API combinations shown is also presented. As a final conclusion, numerous benefits of using the combined preparations should be indicated, especially by the elderly and/or in patients with coexistence of other diseases.
多种疾病是一种越来越常见的现象。其结果是需要进行多药物治疗，这在患有动脉高血压的人群中尤为常见。专门用于治疗高血压的联合制剂（含有至少两种 API-活性药物成分）的开发是为了提高顺应性，特别是在老年患者中。在我们的工作中，我们特别描述了使用β-肾上腺素能受体阻滞剂和血管紧张素转换酶抑制剂联合治疗的可能性。在伴有高血脂症、血液凝固问题和糖尿病等疾病的动脉高血压患者中，API 联合治疗也被作为单一药物使用。我们还依次讨论了 API 联合治疗的药物经济学分析。作为最终结论，应该指出使用联合制剂的诸多益处，特别是对老年人和/或同时患有其他疾病的患者。
